Risk-Stratifying Survivors for Cardiovascular Surveillance
How treatment exposures, baseline cardiovascular risk and symptom status combine into surveillance intensity — and where society guidance agrees and diverges.
Surveillance intensity should follow risk, but risk in survivorship is a composite: what the patient received, what they brought to treatment, and what has happened since. Stratifying on any one of those alone produces either over-imaging of low-risk patients or missed dysfunction in high-risk ones.
Domain one: treatment exposure
Cumulative anthracycline dose, chest or mediastinal radiation with dose and field, HER2-directed therapy, VEGF-pathway inhibitors, proteasome inhibitors, immune checkpoint inhibitors, certain kinase inhibitors, androgen-deprivation therapy, and haematopoietic cell transplant each carry distinct cardiovascular signatures.
Sequential or concurrent exposures are not additive in a simple way — anthracycline followed by chest radiation, or anthracycline plus trastuzumab, are recognised higher-risk combinations rather than a sum of separate risks.
Domain two: host cardiovascular risk
Pre-existing hypertension, diabetes, dyslipidaemia, chronic kidney disease, obesity, smoking, prior cardiac disease, older age at treatment and reduced baseline ejection fraction all raise the probability that a given exposure produces clinical dysfunction.
This domain is also the modifiable one. Blood pressure, lipids, glycaemia, renal function and smoking status are the levers that change trajectory between surveillance studies, and neglecting them while ordering serial imaging treats measurement as management.
Domain three: interval and current status
Symptoms, functional decline, arrhythmia, a change in ejection fraction or global longitudinal strain, and biomarker movement reclassify a patient upward regardless of prior category.
Global longitudinal strain can detect subclinical dysfunction before ejection fraction falls, and where strain is available and reproducible it is increasingly used to trigger earlier cardioprotective intervention.
Turning three domains into an interval
In practice, patients sort into: high risk requiring structured, defined-interval imaging and active risk-factor management; intermediate risk requiring periodic imaging with symptom-triggered escalation; and lower risk managed with standard cardiovascular prevention plus clinical review and symptom-triggered imaging.
Every category needs a named owner and a documented next date. An interval nobody owns is not surveillance.
Where the guidance diverges
Society documents including ASCO survivorship guidance, ESC cardio-oncology guidance, ASE/EACVI imaging statements, NCCN survivorship and COG long-term follow-up guidelines broadly agree on which features constitute high risk. They differ on exact imaging intervals, on the routine role of biomarkers, and on thresholds for initiating cardioprotective therapy.
Publication dates and evidence strength should be surfaced when guidance is compared, and a local pathway should record which source it follows so future updates are traceable.
Frequently asked questions
- Do all survivors need serial echocardiography?
- No. Guideline-based surveillance is concentrated in patients with cardiotoxic exposures or elevated composite risk; lower-risk survivors are generally managed with standard prevention and symptom-triggered imaging.
- Should biomarkers replace imaging in surveillance?
- No. Natriuretic peptides and troponins are used adjunctively in several frameworks, and their routine standalone surveillance role remains less consistently defined across societies than imaging.